NIP
AUPH icon

Nicholas Investment Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Nicholas Investment Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-39,845
Closed -$262K – 199
2019
Q2 		$262K Hold
39,845
– – 0.02% 205
2019
Q1 		$259K Buy
+39,845
New +$264K 0.02% 208
2017
Q3 		– Sell
-254,084
Closed -$1.56M – 248
2017
Q2 		$1.56M Buy
254,084
+2,484
+1% +$16.7K 0.11% 225
2017
Q1 		$1.85M Buy
+251,600
New +$1.16M 0.13% 219

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nicholas Investment Partners's AUPH Position: Q3 2019 in Review

Nicholas Investment Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2019, closing a stake of 39,845 shares — an estimated $262K sold.

Nicholas Investment Partners first reported a position in AUPH in Q1 2017 and held it in 4 quarters. The position peaked at $1.85M in Q1 2017. 72 funds tracked by Wall St. Rank hold AUPH as of Q3 2019.

  • Nicholas Investment Partners reported no remaining Aurinia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Nicholas Investment Partners sold 39,845 Aurinia Pharmaceuticals shares in Q3 2019, an estimated $262K.
  • Nicholas Investment Partners first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Nicholas Investment Partners's Aurinia Pharmaceuticals position peaked at $1.85M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2019.

Based on Nicholas Investment Partners's 13F filing for Q3 2019, filed 13 Nov 2019.